Neon Therapeutics
Neon Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Neon Therapeutics.
Neon Therapeutics is a company.
Key people at Neon Therapeutics.
Neon Therapeutics is a clinical-stage immuno-oncology biotechnology company focused on developing neoantigen-based therapies to treat cancer by directing the patient's immune system against tumor-specific neoantigens, which arise from genetic mutations unique to cancer cells.[1][2][3] The company builds personalized vaccines and T-cell therapies, such as NEO-PV-01 (a neoantigen vaccine in Phase Ib trials for melanoma, non-small cell lung cancer, and bladder cancer) and NEO-PTC-01 (a personalized T-cell therapy), targeting solid tumors and serving patients with advanced or metastatic cancers to address unmet needs in immunotherapy.[1][4][7] Its mission is to create breakthrough oncology treatments that significantly improve patient lives, leveraging a neoantigen platform for both personalized and shared neoantigen approaches across multiple modalities.[1][2][5]
Neon Therapeutics was founded in 2015, emerging from pioneering research by its scientific founders at institutions like the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, who contributed to foundational work in immuno-oncology, including checkpoint inhibitors.[1][5] The company launched with a $55 million Series A financing led by Third Rock Ventures, Clal Biotechnology Industries, and Access Industries, quickly advancing its neoantigen platform based on over a decade of insights into neoantigen biology.[4] Early traction included initiating clinical trials for lead candidates like NEO-PV-01 and collaborations, such as with the Netherlands Cancer Institute for NEO-PTC-01 (planned for 2017 trials) and partnerships with CRISPR Therapeutics (2017) and Natera for enhanced trial assessments.[4][5][7] Leadership evolved with Hugh O’Dowd as CEO from 2016, bringing Novartis Oncology experience, following interim CEO Cary Pfeffer.[4]
Neon Therapeutics rides the immuno-oncology wave, capitalizing on neoantigen biology to pioneer personalized cancer treatments amid rising adoption of precision medicine and combination therapies like vaccines with checkpoint inhibitors.[1][4][5] Timing aligns with post-2015 advances in tumor sequencing and immunotherapy, where neoantigens offer tumor-specific targets, addressing limitations of non-specific treatments amid a surge in clinical trials for solid tumors.[1][2][7] Market forces favoring Neon include expanding oncology pipelines, investor interest in biotech (evident in its Series A and partnerships), and regulatory nods for adaptive trials, influencing the ecosystem by validating neoantigen platforms and fostering collaborations that integrate gene editing (e.g., CRISPR) and monitoring tech.[4][5][6][7]
Neon is poised to advance its pipeline toward proof-of-concept data from NEO-PV-01 and NEO-PTC-01 trials, potentially expanding to more indications like breast cancer with NEO-SV-01, while deepening partnerships for next-gen T-cell engineering.[4][5][7] Trends like AI-driven neoantigen prediction, multimodal combos, and regulatory fast-tracks for personalized therapies will shape its path, amplifying impact in a $100B+ oncology market. Its influence may evolve through acquisitions or IPOs, as hinted in 2018 SEC ambitions for independence, ultimately redefining cancer care around patient-specific neoantigens—echoing its founding mission to transform lives.[1][4]
Key people at Neon Therapeutics.
